Slide 1: BioSyent Inc. Q2/H1 2025 Results
BioSyent BioSyentInc. Inc. Q4 / FY 2023 Q2/H1 2025 Results Results MARCH AUGUST13, 21,2024 2025 PRESENTED BY: RENÉ GOEHRUM PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: 3 | www.biosyent.com | TSXV: RX | www.biosyent.com | TSXV: RX
3 | www.biosyent.com | TSXV: RX 3 | www.biosyent.com | TSXV: RX
Slide 4: Sales, EBITDA and NIAT (Q2)
Sales, EBITDA and NIAT Quarter ended June 30th (Q2) Record Canadian Pharma Quarterly Sales +14% +35% 10,000 EBITDA Margin: 27% to Sales CAD (000's) 5,000 +35% NIAT Margin: 20% to Sales +28% 10,176 7,963 1,860 1,483 8,945 2,048 1,580 2,760 2,018 0 Q2 2023 Q2 2024 Q2 2025 Sales EBITDA NIAT 4 | www.bio
Slide 5: Sales, EBITDA and NIAT (H1)
Sales, EBITDA and NIAT First half ended June 30th (H1) Sales growth from Canadian +27% Pharma, International 20,000 Pharma and Legacy +35% Businesses 15,000 EBITDA Margin: 28% to Sales CAD (000's) 10,000 +40% NIAT Margin: 21% to Sales 5,000 +30% +66% 14,445 16,678 21,158 3,377 2,658 4,252 3,349 5,96
Slide 6: Q2/H1 2025 Sales Summary ($)
Q2/H1 2025 Sales Summary ($) Q2’25 Q2 ‘25 vs. H1’25 H1 ‘25 vs. Sales ($) Q2 ’24 (%) Sales ($) H1 ’24 (%) Canadian Pharma ($) $9,327k +9% $18,487k +15% Cathejell® +1% +8% Combogesic® -22% -26% FeraMAX® Pd +10% +14% Gelclair® -83% -40% Inofolic® -9% +94% RepaGyn® -13% -2% Tibella® (Canada) +28% +39% I
Slide 7: Fully Diluted Earnings per Share (TTM)
Fully Diluted Earnings per Share (TTM) 0.70 60 Consecutive 0.72 0.60 Profitable Quarters to Q2 2025 0.60 0.50 0.40 0.43 0.30 0.20 0.20 0.15 0.20 0.20 0.13 0.18 0.14 0.12 0.12 0.12 0.10 0.09 0.10 0.00 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 TTM
Slide 8: 2025 YTD Highlights
2025 YTD Highlights H1 2025: First Tibelia® Global shipments made by BioSyent: ~$1.3 million in incremental revenue Further orders planned for shipping H2 2025 Mar/Jun 2025: Paid quarterly dividends of $0.05/share (+11% increase vs. 2024) Aug 2025: Q3 2025 Dividend of $0.05/share declared
Slide 9: Trade and Tariffs
Trade and Tariffs Unknowns Remain: USA-Canada Tariffs / Counter-Tariffs Impact on Canadian Consumers Impact on Canadian Economy 9 | www.biosyent.com | TSXV: RX
Slide 10: Most recommended iron supplement in Canada
Most recommended iron supplement in Canada - pharmacists and physicians - 10 consecutive years(1) Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2025 Survey on OTC Counselling and Recomm
Slide 11: FeraMAX LifeCycle Strategy
FeraMAX® LifeCycle Strategy Expanding leadership of FeraMAX® brand in Canada: “Iron health for life” FeraMAX® Pd platform introduced in October 2020 Patented delivery system based on Polydextrose Iron Complex (PDIC) FeraMAX® Pd Therapeutic 150 launched Nov 2020 FeraMAX® Pd Powder 15 launch
Slide 12: Innovations, Product Launches and Acquisitions
Innovations, Product Launches and Acquisitions Tibella® Jul 2020 FeraMAX® Pd Oct 2020 FeraMAX® Pd Therapeutic 150 Nov 2020 Combogesic® Dec 2020 FeraMAX® Pd Powder 15 Oct 2021 FeraMAX® Pd Maintenance 45 Mar 2023 Inofolic® Aug 2023 Gelclair® Nov 2023 Tibelia® Global Sep 2024 New endocrinology asset TB
Slide 13: 15 Years of Profitable Growth (and Counting!)
15 Years of Profitable Growth (and Counting!) Tibelia Global 40,000 Annual Revenue Annual NIAT 35,000 30,000 2010 – 2024 Growth: Revenue 21x 25,000 NIAT 140x CAD 000'S 20,000 15,000 10,000 5,000 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 *2025* f/d shares: 14,336,19
Slide 14: Cash Balance & Return on Equity
Cash Balance & Return on Equity (“RoE”) Trailing Twelve Months ended June 30th 35,000 25% 23% • Zero Debt 21% 30,000 20% • TTM Cash from Operations of 27,785 16% $12.0M 25,000 26,861 25,808 15% • TTM NCIB share buybacks: 20,000 $4.0 M CAD (000's) RoE % 15,000 10% • TTM Dividends of $2.2M 10,000 • Ju
Slide 15: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue/profit growth & portfolio diversification. Capital Light, Cash-Generating Quarterly Dividends Business Model $6.2 M to Date Q4’22 – Q3’25 Share Buybacks $22.6 M to Date 3.1 million shares repurchased since 2018 •7 new
Slide 16: Stock Information
Stock Information As at August 19, 2025 Exchange & Trading Symbol 0% TSXV: RX Aug 19, 2025 Closing Stock Price (CAD) (TSXV): $11.35 52 Week Hi/Low (TSXV): $12.13 / $9.20 Issued Common Shares: 11,474,931 Treasury – RSU Shares in Trust (214,137) Outstanding Common Shares: 11,260,794 Options Outstandin
Slide 17: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 17 www.biosyent.com | TSXV: RX